TORSADES DE POINTES SECUNDARIA A HIPOPOTASEMIA E HIPOMAGNESEMIA: ENFOQUE NEFROCARDIOLÓGICO DEL DIAGNÓSTICO Y MANEJO EN URGENCIAS

Autores/as

Palabras clave:

torsades de pointes; hipopotasemia; hipomagnesemia; QT prolongado; urgencias; nefrología; arritmias ventriculares; síndrome de Gitelman

Resumen

DOI: https://doi.org/10.46296/yc.v10i19.0966

Resumen

Introducción: La torsades de pointes (TdP) es una taquicardia ventricular polimórfica asociada a prolongación del QT que puede degenerar en fibrilación ventricular. La hipopotasemia y la hipomagnesemia reducen la reserva de repolarización y suelen coexistir con fármacos que prolongan el QT, pérdidas gastrointestinales o mecanismos renales de pérdida de electrolitos. Objetivo: sintetizar la presentación clínica, los desencadenantes nefrológicos y farmacológicos, el diagnóstico electrocardiográfico y las estrategias de manejo urgente descritas en reportes y series de casos de TdP asociada a hipopotasemia y/o hipomagnesemia. Métodos: revisión sistemática narrativa siguiendo principios PRISMA 2020. Se realizó una búsqueda focal en PubMed/MEDLINE desde el inicio de la base hasta el 31 de agosto de 2026 y rastreo de referencias. La estrategia principal combinó términos para TdP, hipopotasemia, hipomagnesemia y reportes de caso. Se incluyeron casos con TdP documentada y alteraciones de K+ y/o Mg2+ clínicamente relevantes. La calidad de reporte se valoró con dominios de las herramientas JBI para reportes/series de casos. Resultados: la búsqueda focal recuperó 43 registros. Quince reportes individuales fueron retenidos para la síntesis estructurada. El rastreo de referencias identificó además una cohorte de 48 pacientes con TdP, utilizada como evidencia contextual complementaria. Los mecanismos recurrentes fueron pérdidas gastrointestinales, diuréticos, fármacos que prolongan el QT, síndrome de Gitelman, tubulopatía Bartter-like inducida por colistina, hemodiálisis y depleción asociada a alcohol. El manejo exitoso combinó suspensión de desencadenantes, sulfato de magnesio intravenoso, corrección intensiva de potasio, desfibrilación cuando existió inestabilidad y aumento de la frecuencia cardíaca mediante marcapasos o isoproterenol en TdP dependiente de pausas. Conclusiones: la TdP por alteraciones de K+ y Mg2+ debe entenderse como una urgencia nefrocardiológica. La estabilización eléctrica inmediata debe acompañarse de una búsqueda dirigida de pérdidas renales y extrarrenales, revisión farmacológica y prevención de recurrencias.

Palabras claves: torsades de pointes; hipopotasemia; hipomagnesemia; QT prolongado; urgencias; nefrología; arritmias ventriculares; síndrome de Gitelman.        

Abstract

Background: Torsades de pointes (TdP) is a polymorphic ventricular tachycardia associated with QT prolongation and may deteriorate into ventricular fibrillation. Hypokalemia and hypomagnesemia reduce repolarization reserve and frequently coexist with QT-prolonging drugs, gastrointestinal losses, or renal electrolyte-wasting mechanisms. Objective: To synthesize clinical presentation, nephrologic and pharmacologic triggers, electrocardiographic diagnosis, and emergency management strategies reported in case reports and series of TdP associated with hypokalemia and/or hypomagnesemia. Methods: Narrative systematic review conducted according to PRISMA 2020 principles. PubMed/MEDLINE was searched from inception through August 31, 2026, complemented by reference tracking. The primary strategy combined terms for TdP, hypokalemia, hypomagnesemia, and case reports. Cases were eligible when TdP was documented and clinically relevant K+ and/or Mg2+ abnormalities were reported. Reporting quality was appraised using JBI case-report/case-series domains. Results: The focused search retrieved 43 records. Fifteen single-patient reports were retained for structured synthesis. Reference tracking additionally identified a cohort of 48 patients with TdP, used as complementary contextual evidence. Recurrent mechanisms included gastrointestinal losses, diuretics, QT-prolonging drugs, Gitelman syndrome, colistin-induced Bartter-like tubulopathy, hemodialysis, and alcohol-related depletion. Successful treatment consistently combined trigger withdrawal, intravenous magnesium sulfate, intensive potassium correction, defibrillation for unstable episodes, and heart-rate acceleration with pacing or isoproterenol in pause-dependent TdP. Conclusions: Electrolyte-mediated TdP should be managed as a nephrocardiology emergency. Electrical stabilization must be coupled with targeted assessment of renal and extrarenal losses, medication review, and recurrence prevention.

Keywords: torsades de pointes; hypokalemia; hypomagnesemia; long QT; emergency medicine; nephrology; ventricular arrhythmia; Gitelman syndrome.

Información del manuscrito:
Fecha de recepción:
17 de abril de 2026.
Fecha de aceptación: 22 de junio de 2026.
Fecha de publicación: 10 de julio de 2026.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259(1):59-69. doi:10.1111/j.1365-2796.2005.01589.x.

Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719-1726. doi:10.1185/03007995.2013.840568.

Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012:212178. doi:10.1100/2012/212178.

Wigginton JG, et al. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(Suppl 2):S538-S577. doi:10.1161/CIR.0000000000001376.

Thomas SHL, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016;81(3):420-427. doi:10.1111/bcp.12726.

Windley MJ, et al. Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. Biophys Rev. 2022;14(1):353-367. doi:10.1007/s12551-022-00929-7.

Agus ZS. Hypomagnesemia: renal magnesium handling. Semin Nephrol. 1998;18(1):58-73.

Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a KDIGO Controversies Conference. Kidney Int. 2017;91(1):24-33. 10.1016/j.kint.2016.09.046.

JCS/JHRS. JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2022;86:1790-1924.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. 10.1136/bmj.n71.

Joanna Briggs Institute. Critical Appraisal Tools for Case Reports and Case Series. JBI Manual for Evidence Synthesis. Adelaide: JBI; 2024.

Chvilicek JP, Hurlbert BJ, Hill GE. Diuretic-induced hypokalaemia inducing torsades de pointes. Can J Anaesth. 1995;42(12):1137-1139. doi:10.1007/BF03015102.

Balaji S, Sethuraman KR, Sundararaman T. Hypomagnesemia with hypokalemia in an uncontrolled diabetic patient presenting with recurrent episodes of torsades de pointes. J Assoc Physicians India. 1999;47(6):645-646.

Lin AH, et al. Overdrive pacing in a patient with incessant torsades de pointes. BMJ Case Rep. 2013;2013:bcr2013200146. doi:10.1136/bcr-2013-200146.

Al Banna R, Husain A, Al-Ghamdi B. Ventricular arrhythmia and tachycardia-induced cardiomyopathy in Gitelman syndrome, hypokalaemia is not the only culpable. BMJ Case Rep. 2019;12(12):e232086. doi:10.1136/bcr-2019-232086.

Yang JA, Choi HS, Bae EH, Ma SK, Kim SW, Kim CS. Torsade de pointes in initiating hemodialysis: a case report. Ann Palliat Med. 2020;9(3):1264-1268. doi:10.21037/apm.2020.04.29.

Yonai R, Kawabata M, Maeda S, et al. Torsade de pointes induced by intravenous amiodarone therapy accompanied by marked augmentation of the transmural dispersion of repolarization in a patient with tachycardia-induced-cardiomyopathy. Ann Noninvasive Electrocardiol. 2021;26:e12810. doi:10.1111/anec.12810.

Durán-Torres F, et al. Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation. BMC Cardiovasc Disord. 2021;21:136. doi:10.1186/s12872-021-01945-3.

Tiver KD, Dharmaprani D, Quah JX, Lahiri A, Waddell-Smith KE, Ganesan AN. Vomiting, electrolyte disturbance, and medications; the perfect storm for acquired long QT syndrome and cardiac arrest: a case report. J Med Case Rep. 2022;16(1):9. doi:10.1186/s13256-021-03204-7.

Cole JB, et al. QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron. Am J Emerg Med. 2023;68:214.e3-214.e6. doi:10.1016/j.ajem.2023.04.003.

Solaimanzadeh I. A Rare Presentation of Levetiracetam-Induced Torsades De Pointes. Cureus. 2023;15(6):e40866. doi:10.7759/cureus.40866.

Idries IY, Azhar M, Yadav R, et al. Heart's Dangerous Symphony: Torsade De Pointes Unleashed by Gitelman Syndrome-Induced Hypomagnesemia. Cureus. 2023;15(8):e44464. doi:10.7759/cureus.44464.

Khan M, Kabir N, Mody S, Essop T, Urciuoli D. Torsades de Pointes Following Massive Transfusion Protocol: Case Highlighting Electrolyte Disturbances After Blood Product Administration. JACC Case Rep. 2025;30(25):104795. doi:10.1016/j.jaccas.2025.104795.

Ishii K, Onuki T, Nakamura E, et al. Recurrent syncope attributed to torsade de pointes induced by worsened long QT interval after switching from peritoneal dialysis to hemodialysis: A case report. J Cardiol Cases. 2025;31(3):84-87. doi:10.1016/j.jccase.2024.12.003.

Gupta A, et al. Colistin-Induced Bartter-Like Syndrome With Torsades de Pointes: A Reversible Cause of Life-Threatening Arrhythmia. JACC Case Rep. 2025;30(39):106141. doi:10.1016/j.jaccas.2025.106141.

Zhang R, Zhao L, Li S, et al. Recurrent Ventricular Arrhythmia From Acquired Long QT Syndrome Due to Alcohol-Related Electrolyte Depletion. JACC Case Rep. 2026;31(5):105942. doi:10.1016/j.jaccas.2025.105942.

Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Front Pharmacol. 2018;9:363. doi:10.3389/fphar.2018.00363.

Tisdale JE, et al. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139-152. doi:10.1177/1715163516641136.

Woosley RL, et al. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14(11):747-753. doi:10.1002/pds.1112.

Descargas

Publicado

2026-07-10

Cómo citar

Morocho-Saldarriaga, K. F., Cruz-Sanabria, J. C., Galarza-Ibáñez, D. L., Zhunio-Uyaguari, K. S., & Torres-Naula, M. del C. (2026). TORSADES DE POINTES SECUNDARIA A HIPOPOTASEMIA E HIPOMAGNESEMIA: ENFOQUE NEFROCARDIOLÓGICO DEL DIAGNÓSTICO Y MANEJO EN URGENCIAS. REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN - ISSN: 2697-3456, 10(19), 841–854. Recuperado a partir de https://editorialibkn.com/index.php/Yachasun/article/view/1047